COVID-19 vaccine developments
…point. Instead, the endpoint being studied in the trials is the risk of symptomatic COVID-19 of any severity, including mild infections, as FDA indicated it was willing to grant emergency use on that basis. The problem is that because mild COVID-19 is far more common than COVID-19 hospitalizations and deaths, and because the trials appear…
